A patient with two gliomas with independent oligodendroglioma and glioblastoma biology proved by DNA-methylation profiling: a case report and review of the literature

Abstract

Here, we report on a patient presenting with two histopathologically distinct gliomas. At the age of 42, the patient underwent initial resection of a right temporal oligodendroglioma IDH mutated 1p/19q co-deleted WHO Grade II followed by adjuvant radiochemotherapy with temozolomide. 15 months after initial diagnosis, the patient showed right hemispheric tumor progression and an additional new left frontal contrast enhancement in the subsequent imaging. A re-resection of the right-sided tumor and resection of the left frontal tumor were conducted. Neuropathological work-up showed recurrence of the right-sided oligodendroglioma with features of an anaplastic oligodendroglioma WHO Grade III, but a glioblastoma WHO grade IV for the left frontal lesion. In depth molecular profiling revealed two independent brain tumors with distinct molecular profiles of anaplastic oligodendroglioma IDH mutated 1p/19q co-deleted WHO Grade III and glioblastoma IDH wildtype WHO grade IV. This unique and rare case of a patient with two independent brain tumors revealed by in-depth molecular work-up and epigenomic profiling emphasizes the importance of integrated work-up of brain tumors including methylome profiling for advanced patient care.

Anti-cancer and neuroprotective effects of conjugated graphene quantum dot in brain tumor-bearing rat model

“…The lambda tumor-induced group, plain GQD treated, GQD-BSA conjugate treated, and GQD-Trastuzumab conjugate treated groups showed disturbed and altered cell bodies with extracellular space, scar formation, and hippocampal gliosis. While the GQD-Caspase 8 conjugate-treated group showed recuperate changes in damaged cell structures, reduced inflammation, and neurodegeneration [71,72].…”

Methylome Profiling of PD-L1-Expressing Glioblastomas Shows Enrichment of Post-Transcriptional and RNA-Associated Gene Regulation

“…Molecular genetic analyses for IDH1 , IDH2 mutations, as well as DNA methylation were performed as previously described [ 26 , 27 , 28 ]. In brief, representative tumor regions were microscopically identified and dissected.…”

“…Mutational analysis of IDH1 and IDH2 genes was performed with either the AmpliSeq for Illumina Cancer Hotspot Panel v2 (Illumina, San Diego, CA, USA) or the AmpliSeq for Illumina Focus Panel (Illumina), respectively. Next generation sequencing was performed on an Illumina MiniSeq device following the manufacturer’s protocol [ 26 , 27 , 28 ].…”

“…Telomerase reverse transcriptase mutation analysis and MGMT methylation analysis were performed as described previously [ 26 , 27 , 28 ].…”

“…Methylation analysis was performed using the Infinium Methylation EPIC Bead Chip (Illumina) protocol [ 26 , 27 , 28 ]. Raw data files (idat-files) were analyzed using the molecularneuropathology.org bioinformatics pipeline of the German Cancer Research Center (DKFZ) and the v11b4 brain tumor classifier [ 29 ].…”